- Jul 2018
-
europepmc.org europepmc.org
-
On 2014 Aug 27, Jim Woodgett commented:
Regarding the inhibitor used, SB415286, a quote from reference 29 (Coghlan et al. PMID: 11033082), "SB-216763 and SB-415286 are structurally distinct maleimides that inhibit GSK-3alpha in vitro, with Ki's of 9 nM and 31 nM respectively, in an ATP competitive manner. These compounds inhibited GSK-3beta with similar potency."
As such, the >25 references in this study to specific inhibition of GSK-3beta should be replaced by GSK-3 as both isoforms (alpha and beta, which are ubiquitously expressed) will be similarly inhibited by this compound.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-
- Feb 2018
-
europepmc.org europepmc.org
-
On 2014 Aug 27, Jim Woodgett commented:
Regarding the inhibitor used, SB415286, a quote from reference 29 (Coghlan et al. PMID: 11033082), "SB-216763 and SB-415286 are structurally distinct maleimides that inhibit GSK-3alpha in vitro, with Ki's of 9 nM and 31 nM respectively, in an ATP competitive manner. These compounds inhibited GSK-3beta with similar potency."
As such, the >25 references in this study to specific inhibition of GSK-3beta should be replaced by GSK-3 as both isoforms (alpha and beta, which are ubiquitously expressed) will be similarly inhibited by this compound.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-